Demineralized Bone Matrix (DBM) & Osteoinductive Technologies
U.S. 9,415,136 — Osteoinductive Demineralized Cancellous Bone
U.S. 8,202,539 — Bone Matrix Compositions and Methods
Founder Accomplishments
U.S. 9,415,136 — Osteoinductive Demineralized Cancellous Bone
U.S. 8,202,539 — Bone Matrix Compositions and Methods
U.S. 9,333,237 — BMP Binding Peptide
U.S. 9,610,320 — Surgical Application of BBP
U.S. 8,642,061 — Viral Inactivation of Tissue Grafts
U.S. 10,220,115 — Bone Matrix Nano-Textured Surfaces
U.S. 9,717,822 — Surgical Graft / Delivery System
Conceived the product concept in response to a strategic initiative to develop procedure-specific bone grafts beyond general-use DBM products. Led scientific development and commercialization of the enhanced demineralized bone matrix (DBM) platform, including product development, biological characterization, and support of FDA regulatory clearance.
Supported engineering efforts by identifying titanium plasma spray (TPS) as the preferred surface roughening technology following characterization of osteoblast responses to multiple surface treatments in tissue culture.
Supported engineering efforts by investigating prototype failures using scanning electron microscopy (SEM) and energy-dispersive spectroscopy (EDS). Identified fracture nucleation associated with print media contamination and recommended alternative titanium print media that resolved the issue.
Developed the formulation, final product configuration, and delivery system. Supported manufacturing scale-up and established the product's technical market positioning.